In Vitro and In Vivo Human Metabolism of Ostarine, a Selective Androgen Receptor Modulator and Doping Agent
Authors:
- Omayema TaoussiOTOmayema Taoussi
- Giulia BambagiottiGBGiulia Bambagiotti
- Prince Sellase GameliPGPrince Sellase Gameli
- Gloria DazianiGDGloria Daziani
- Francesco TavolettaFTFrancesco Tavoletta
- Anastasio TiniATAnastasio Tini
- Giuseppe BasileGiuseppe Basile
- Alfredo Fabrizio Lo FaroAFAlfredo Fabrizio Lo Faro
- Jeremy CarlierJeremy Carlier
Open Access
- 17 July 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (14) , 7807
Abstract
Ostarine (enobasarm) is a selective androgen receptor modulator with great therapeutic potential. However, it is also used by athletes to promote muscle growth and enhance performances without the typical adverse effects of anabolic steroids. Ostarine popularity increased in recent years, and it is currently the most abused “other anabolic agent” (subclass S1.2. of the “anabolic agents” class S1) from the World Anti-Doping Agency’s (WADA) prohibited list. Several cases of liver toxicity were recently reported in regular users. Detecting ostarine or markers of intake in biological matrices is essential to document ostarine use in doping. Therefore, we sought to investigate ostarine metabolism to identify optimal markers of consumption. The substance was incubated with human hepatocytes, and urine samples from six ostarine-positive cases were screened. Analyses were performed via liquid chromatography–high-resolution tandem mass spectrometry (LC-HRMS/MS) and software-assisted data mining, with in silico metabolite predictions. Ten metabolites were identified with hydroxylation, ether cleavage, dealkylation, O-glucuronidation, and/or sulfation. The production of cyanophenol-sulfate might participate in the mechanism of ostarine liver toxicity. We suggest ostarine-glucuronide (C25H22O9N3F3, diagnostic fragments at m/z 118, 185, and 269) and hydroxybenzonitrile-ostarine-glucuronide (C25H22O10N3F3, diagnostic fragments at m/z 134, 185, and 269) in non-hydrolyzed urine and ostarine and hydroxybenzonitrile-ostarine (C19H14O4N3F3, diagnostic fragments at m/z 134, 185, and 269) in hydrolyzed urine as markers to document ostarine intake in doping.Keywords
Funding Information
- Italian Ministry of Health (Ministero della Salute)
This publication has 32 references indexed in Scilit:
- In silico, in vitro, and in vivo human metabolism of acetazolamide, a carbonic anhydrase inhibitor and common “diuretic and masking agent” in dopingArchives of Toxicology, 2022
- Elimination profiles of microdosed ostarine mimicking contaminated products ingestionDrug Testing and Analysis, 2020
- Identification of S22 (ostarine) in human nails and hair using LC‐HRMS. Application to two authentic casesDrug Testing and Analysis, 2020
- Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-AnalysisSports Medicine, 2017
- Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatinInvestigational New Drugs, 2016
- Investigation of the selective androgen receptor modulators S1, S4 and S22 and their metabolites in equine plasma using high‐resolution mass spectrometryRapid Communications in Mass Spectrometry, 2016
- Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functionsReviews in Endocrine and Metabolic Disorders, 2015
- Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S‐22 to identify potential targets for routine doping controlsRapid Communications in Mass Spectrometry, 2011
- Characterization of in vitro generated metabolites of the selective androgen receptor modulators S‐22 and S‐23 and in vivo comparison to post‐administration canine urine specimensDrug Testing and Analysis, 2010
- Discovery of Nonsteroidal AndrogensBiochemical and Biophysical Research Communications, 1998